This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Biodexa Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Biodexa Pharmaceuticals şirketinin toplam hissedar öz sermayesi £7.5M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £9.7M ve £2.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£6.42m
Eşitlik	UK£7.49m
Toplam yükümlülükler	UK£2.19m
Toplam varlıklar	UK£9.68m

Son finansal sağlık güncellemeleri

Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

May 17

Recent updates

Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

May 17

Midatech Pharma plc (LON:MTPH) Insiders Have Been Selling

Feb 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BDRX 'nin kısa vadeli varlıkları ( £8.7M ) kısa vadeli yükümlülüklerini ( £1.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: BDRX şirketinin kısa vadeli varlıkları ( £8.7M ) uzun vadeli yükümlülüklerini ( £546.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BDRX borçsuzdur.

Borcun Azaltılması: BDRX şirketinin 5 yıl önce borç/öz sermaye oranı 4.8% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BDRX şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: BDRX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

This company listing is no longer active

Biodexa Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma plc Announces Receipt of Nasdaq Notification

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

Recent updates

Midatech Pharma plc announced that it has received $5.999223 million in funding

Midatech Pharma Announces Receipt of NASDAQ Notice

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Midatech Pharma plc (AIM:MTPH) entered into a definitive agreement to acquire Bioasis Technologies Inc. (TSXV:BTI) from The Lind Partners, LLC and others for $5.5 million.

Midatech Pharma plc announced that it expects to receive $10 million in funding

Midatech Pharma plc Announces First Patient Enrolled in Phase 1 Study of MTX-110

Midatech Pharma plc Announces Receipt of Nasdaq Notification

First half 2022 earnings released: UK£0.031 loss per share (vs UK£0.05 loss in 1H 2021)

Midatech Pharma PLC Announces Directorate Change

Midatech Pharma plc Announces MTX110 Study to be Presented at ISPNO 2022

Midatech Pharma plc Announces Retirement of Rolf Stahel

Midatech Pharma plc Announces Fast Track Designation Granted to Mtx110 Development for the Treatment of Recurrent Glioblastoma

Midatech Pharma plc, Annual General Meeting, Jun 20, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Midatech Pharma Received Written Notification from Nasdaq Stating Company Is Not in Compliance with Minimum Bid Price Requirement

Midatech Pharma PLC Announces Investigational New Drug Application for Study of MTX110 in Recurrent Glioblastoma (GBM) Becomes Effective

First half 2021 earnings released: UK£0.05 loss per share (vs UK£0.64 loss in 1H 2020)

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £10 million.

Midatech Pharma plc Announces Shut Down of its Bilbao Operations

Here's Why Midatech Pharma (LON:MTPH) Must Use Its Cash Wisely

Midatech Pharma plc (LON:MTPH) Insiders Have Been Selling

New 90-day high: UK£0.42

New 90-day high: UK£0.34

Midatech Pharma PLC to Present MTX110 Programmes at The International Symposium on Pediatric Neuro-Oncology, Karuizawa, Japan

New 90-day low: UK£0.27

Midatech Pharma plc Announces Headline Results of MTX110 Phase I DIPG Study

First half earnings released

Midatech Pharma plc to Report First Half, 2020 Results on Sep 10, 2020

Midatech Pharma plc has completed a Follow-on Equity Offering in the amount of £5 million.

New 90-day high - UK£0.86

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin